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Studies in fibroblasts, neurons, and 
platelets have demonstrated the integration of 
signals from different G-protein coupled 
receptors (GPCRs) in raising intracellular 
free Ca2+.  To study signal integration in 
macrophages, we screened RAW264.7 cells 
and bone marrow-derived macrophages 
(BMDM) for their Ca2+ response to GPCR 
ligands.  We found a synergistic response to 
complement component 5a (C5a) in 
combination with uridine 5’-diphosphate 
(UDP), platelet activating factor (PAF) or 
lysophosphatidic acid (LPA).  The C5a 
response was Gαi-dependent, while the UDP, 
PAF, and LPA responses were Gαq-
dependent. Synergy between C5a and UDP, 
mediated by the C5a and P2Y6 receptors, 
required dual receptor occupancy, and 
affected the initial release of Ca2+ from 
intracellular stores as well as sustained Ca2+ 
levels.  C5a and UDP  synergized in 
generating inositol-1,4,5-trisphosphate, 
suggesting synergy in activating 
phospholipase C (PLC) β.  Macrophages 
expressed transcripts for three PLCβ 
isoforms (PLCβ2, PLCβ3, and PLCβ4), but 
GPCR ligands selectively used these isoforms 
in Ca2+ signaling.  C5a predominantly used 
PLCβ3, while UDP used PLCβ3 but also 
PLCβ4.  Neither ligand required PLCβ2.  
Synergy between C5a and UDP likewise 
depended primarily on PLCβ3.  Importantly, 
the Ca2+ signaling deficiency observed in 
PLCβ3-deficient BMDM was reversed by re-
constitution with PLCβ3. Neither PI-3 kinase 
nor PKC was required for synergy.  In 
contrast to Ca2+, PI3-kinase activation by C5a 
was inhibited by UDP, as was 
macropinocytosis, which depends on PI3-
kinase.  PLCβ3 may thus provide a selective 
target for inhibiting Ca2+ responses to 
mediators of inflammation, including C5a, 
UDP, PAF, and LPA. 
Calcium is an important messenger involved 
in the regulation of multiple cellular processes, 
and levels of intracellular free calcium ([Ca2+]i) 
are precisely regulated (1-3).   Increases in 
intracellular [Ca2+]i are initiated by the 
phospholipase C (PLC) family of enzymes, 
which hydrolyze membrane-associated 
phosphatidylinositol-4,5-diphosphate (PIP2) to 
produce inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) (4). IP3 triggers the 
release of Ca2+ from stores in the endoplasmic 
reticulum, while DAG activates members of the 
protein kinase C (PKC) family.  Following 
activation of stored Ca2+ by IP3, influx of 
extracellular Ca2+ across the plasma membrane 
may further contribute to an increase in [Ca2+]i, 
which is regulated by several Ca2+ pumps and 
buffers (1).  The net level and duration of these 
Ca2+ signals regulate cellular responses, 
including transcription, apoptosis, endocytosis, 
chemotaxis, and metabolism (3). 
Simultaneous stimulation of two GPCRs 
coupled to different Gα subunits, often Gαi or 
Gαs in combination with Gαq, has been shown 
to yield synergistic Ca2+ responses in several 
model systems (reviewed in (5)).  Limited 
studies have demonstrated this synergy in 
primary cells, including neurons and platelets, 
but the mechanisms of synergy vary and are not 
well defined (6,7).  
Synergistic Ca2+ responses resulting from 
heterologous GPCR ligation have been little 
studied in macrophages, where members of the 
GPCR superfamily can stimulate an increase in 
[Ca2+]i by activating members of the PLCβ 
family (4).  As part of a systematic screen of 
RAW264.7 macrophage cells, C5a and UDP 
demonstrated synergy in producing a rise in 
[Ca2+]i (http://www.signaling-gateway.org/data/ 
cgi-bin/table2.cgi?cellabbr=RW) (8)).  C5a is an 
important inflammatory mediator for 
macrophages and UDP, which is released 
following cell damage, is also present at sites of 
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injury or infection (9,10).  Both ligands signal 
through GPCRs; C5a signals through C5aR (11), 
and UDP signals through P2Y6 receptors (12).  
To examine GPCR cross-talk by these ligands in 
mouse macrophages we studied both RAW264.7 
cells and primary bone marrow-derived 
macrophages (BMDMs)  
Our studies show that signals generated by 
C5a and UDP, acting through Gαi- and Gαq-
coupled pathways respectively, converge at the 
level of PLCβ, and that these ligands, both 
individually and in concert, selectively use one 
PLCβ isoform, PLCβ3, to activate the 
production of IP3 and the consequent release of 
Ca2+ from intracellular stores.  
 
EXPERIMENTAL PROCEDURES 
 
Reagents. UDP, UTP, LPA, PAF, human 
C5a, and FITC-dextran were from Sigma-
Aldrich.  Mouse IgG2a was from BD 
Pharmaceuticals. F(ab’)2 fragment of goat anti-
mouse IgG was from Jackson Immunoresearch 
Inc.  Anti-PLCβ3 was from P. Sternweis, 
UTSW.  Anti-P-Akt and anti-P-ERK were from 
Cell Signaling Technologies.  Fura2 was from 
Molecular Probes.  Ionomycin, thapsigargin, 
pertussis toxin, LY294002, wortmannin, 
Calphostin C, staurosporine, U-73122, and U-
73343 were from Calbiochem.  Additional 
detailed protocols for reagents, procedures, and 
solutions are available on the internet 
(www.afcs.org and www.signaling-gateway.org) 
and are referenced according to protocol number 
(eg. PP00000226). 
Culture of RAW264.7 cells is described in 
protocol PP00000226. Following lentiviral 
infection, positive transductants were selected 
by antibiotic resistance conferred by the 
particular viral construct used (PP00000206).  
These included puromycin (2 µg ml), G418 
(100-500 µg/ml), hygromycin (50 µg/ml), and 
zeocin (100 µg/ml).  Detailed specifications for 
each medium are available at 
http://www.signaling-gateway.org/data/cgi-bin/ 
Protocols.cgi?cat=3. 
Mice and culture of BMDM.  Mice 
genetically deficient in Gαq, Gα11, PLCβ3, 
PLCβ4 or PLCβ2 were previously described 
(13-19).  All strains were on the C57BL/6 
background except PLCβ2-deficient mice, 
which were on 129SV.  Genetically deficient 
and corresponding wild-type (wt) strains were 
bred and housed under approved animal 
protocols.  For BMDM culture femurs and tibias 
were removed from sex- and age-matched mice 
(4-20 weeks of age, matched +/- 4 weeks) 
(PP0000017200). Briefly, marrow was flushed 
from bones, erythrocytes were lysed, and the 
white cells were seeded in non-tissue culture 
Petri dishes for selection by growth and 
adhesion.  After 6 days, over 99% of the 
surviving cells were macrophages, and these 
cells were maintained for up to 35 days in 
culture. Cells were cultured overnight in tissue 
culture (TC) plates prior to use in assays.    
Lentivirus-mediated RNAi. Lentivirus was 
produced with a combination of three plasmids: 
(i) pCMV∆R8.91 packaging plasmid, (ii) 
pMD.G envelope plasmid (20,21), and (iii) a 
lentiviral vector plasmid (http://www.signaling-
gateway.org/data/plasmid). The packaging and 
envelope plasmids were generously provided by 
D. Trono, Geneva. The lentiviral vector 
plasmids contained shRNA sequences expressed 
under RNA polymerase III promoters (U6 or 
H1) upstream of a Ubi-C promoter driving 
bicistronic expression of either EGFP or an 
hCD4 marker, followed by a resistance gene for 
either puromycin or hygromycin (22).  
Transfection of the 3 plasmids into 293T cells 
utilized lipofectamine 2000 (Invitrogen) and 20 µg of total DNA in a ratio of 4:3:2 for vector, 
packaging, and envelope plasmids respectively 
(PP00000200).  Two days post-transfection, 
lentivirus was concentrated by using Centricon 
microfiltration tubes (PP00000202).  
Macrophages were infected at a multiplicity of 
infection of ~10 in the presence of polybrene at 
4 µg/ml (PP00000215) (22).  shRNAs targeting 
murine PLCβ2, PLCβ3 and PLCβ4 employed 
the sequences  GAA CAG AAG TTA CGT TGT 
C,  GCA GCG AGA TGA TTT GAT T, and 
ACG CGA TTG AGT TTG TAA ATT A, 
respectively. 
Retrovirus-mediated transduction of 
macrophages with PLCβ. pFB-neo vectors 
carrying YFP-tagged murine PLCβ3 or YFP-
FLAG epitope were transfected into the PlatE 
packaging line (23) to produce ecotropic 
retroviruses for transduction of day-2 cultures of 
bone marrow cells, which were differentiated 
into BMDM as described above. 
Population calcium assays.  Ca2+ responses 
were measured by monitoring the fluorescence 
of Fura-2-loaded cells (PP00000211). Baseline 
readings were collected for 30-40 sec.  
Calibration steps included additions of a Ca2+-
minimizing solution (PS00000607) and Fura-2 
Ca2+-saturating solution (PS00000608) at the 
end of each recording, to allow calculation of 
[Ca2+]i values according to the method of 
Grynkiewicz (24), assuming a cytoplasmic Kd of 
250 nM for Fura-2.  Ca2+ signals during the 
response period were quantified by features as 
indicated, including the peak offset response 
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(difference between baseline Ca2+ level and the 
maximal Ca2+ level observed, reported in nM) 
and an integrated response (integrated Ca2+ level 
above the average baseline over the indicated 
time period, reported in nM x seconds). 
Single-cell calcium assays. BMDM were 
plated in chambered coverglasses (Nunc, 8 
wells/coverglass), cultured overnight, and 
loaded with Fura-2-AM as described above. 
Video microscopy was performed on a Nikon 
TE-300 fluorescence microscope equipped with 
a Photometrics HQ2 camera, 37°C stage 
incubator (Bionomics), Xe lamp (Sutter), and 
filter/shutter/dichoric controllers (Sutter and 
Conix). SimplePCI software was used to control 
collection parameters and extract fluorescence 
intensity data for individual cells. 
IP3 assay.  After cell culture overnight, cells 
were placed in serum-free medium containing, 
0.01% BSA. After 1 hr, ligands were added and, 
after varied time periods, dishes were transferred 
to ice, the media aspirated, and the cells washed 
with cold PBS.  Cells were scraped into 125 µl 
of 5.4% perchloric acid solution and transferred 
to siliconized microfuge tubes on ice.  Samples 
were centrifuged at 14,000xg for 15 min at 4°C.  
120 µl of supernatant was neutralized with 5 N 
KOH containing 60 mM HEPES, and the 
samples were recentrifuged at 14,000xg for 15 
min at 4°C.  The IP3 content of the final 
supernatant was assayed with an Amersham IP3 
[3H] Biotrak assay kit. Results were reported as 
pmoles IP3 per 106 cells.  
SDS-PAGE and Western blot analysis of 
phosphoproteins (protocols PP00000168 and 
PP00000181).  Cells were stimulated under the 
same conditions used for the IP3 assay. Then 
buffer was aspirated, the cells were scraped into 
Laemelli sample buffer, and the samples were 
heated.  SDS-PAGE gels were loaded with 20 µg protein per lane, and Western blots were 
probed with anti-P-Akt, anti-P-ERK, and anti-
Rho-GDI.  Fluorescent signals, measured for P-
Akt and P-ERK by using a phosphoimager, were 
normalized to Rho-GDI. 
Macropinocytosis assay.  Macropinocytosis 
was assessed by measuring the cellular uptake of 
fluorescently labeled FITC-dextran. In brief, 
BMDM cells were cultured overnight in non-TC 
plates.  Medium was replaced with Hank’s 
Balanced Salt Solution with 1 mg/ml BSA, pH 
7.4.  After 1 hr ligands were added together with 
FITC-dextran (150 KDa MW, Sigma, 1 mg/ml 
final concentration in well).  Activity was 
stopped with cold medium.  After washing, cells 
were harvested in PBS with 5 mM EDTA and 5 
mg/ml BSA, and analyzed by flow cytometry 
(FACSCalibur, BD) in 0.4% trypan blue 
solution (Sigma) to quench extracellular 
fluorescence. Ligand-stimulated activity was 
expressed as a ratio (‘fold stimulation’) to 
baseline activity.  
Statistical Analyses.  The error bars in 
graphs depict the standard error of the mean. 
The statistical significance of each comparison 
was evaluated by performing Student's t-tests for 
one-way analysis of variance, followed by 
Dunnett or individual t-tests (with Bonferroni 
correction), or non-linear mixed effects 
modeling, as appropriate.  The effects of RNAi 
on Ca2+ responses in RAW264.7 cells were 
analyzed by non-linear mixed-effects modeling 
because of  the non-normal distribution of Ca2+ 
response features, and because of variation in 
responses between cell lines and assays.  A p-
value of <0.05 was considered significant. 
 
RESULTS 
 
UDP and C5a interact to produce a 
synergistic calcium response in macrophages.  
As part of a large-scale screen, we observed a 
synergistic interaction between UDP and C5a 
for Ca2+ signaling (http://www.signaling-
gateway.org/data/cgi-bin/table2.cgi?cellabbr= 
RW).  This response showed a faster rise time 
and an increased peak-offset (peak response 
minus baseline) compared to the predicted 
additive response by the individual ligands (Fig. 
1A).  For the peak offset, the observed dual-
ligand response was increased by 1.5 to 2-fold 
over the predicted additive response.  Integration 
of the response over the first 20 sec yielded 
similar values. The ratio of observed/predicted 
values for such features of the response was 
referred to as the synergy ratio.  BMDM showed 
a similar synergistic increase in the Ca2+ 
response, but the synergy ratio was much greater 
than in RAW264.7 cells (Fig. 1B). 
For both cell types the optimal synergistic 
concentrations of each ligand were at or near the 
threshold for stimulation (Fig. 1C for BMDM, 
RAW264.7 data not shown).  Synergy was 
nonetheless still observed at higher 
concentrations of both ligands, which fell within 
the linear portions of their dose-response curves.  
For RAW 264.7 cells, optimal concentrations for 
synergy were 0.25-100 nM C5a and 40-500 nM 
UDP, while for BMDM they were 0.1-3 nM C5a 
and 150-500 nM UDP. 
Synergy is dependent on signaling through 
both Gαi- and Gαq- dependent GPCRs. C5a 
engages C5aR, which signals predominantly 
through Gαi-coupled heterotrimers (11,25,26). 
Thus, in BMDM and in RAW264.7, the Ca2+ 
response to C5a was inhibited following 
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treatment with pertussis toxin (Ptx), whereas that 
of UDP was not (Fig. 2A and supplemental Fig. 
S1).  Ptx-mediated inhibition of signaling by low 
concentrations of C5a (<1 nM) was complete, 
but at high concentrations residual Ptx-
insensitive calcium signaling was detected both 
in WT BMDM and in BMDM from mice 
lacking either Gαq or Gα11 (data not shown). 
Saturation of Ptx-intoxication of the C5a Ca2+ 
response was reached using 5 ng/ml for 18 hr, 
(supplemental Fig. S1) Others have 
demonstrated a role for Gα15 in C5a signaling 
in primary macrophages (27).  While our data 
indicate that most C5a signaling is Ptx-sensitive, 
they are consistent with some signaling through 
Gα15 when C5a is present in high 
concentration.  The Ca2+ response to C5a in 
BMDM from mice genetically deficient in Gαi2 
was intact (data not shown), suggesting that 
Gαi3 is sufficient to support C5a signaling in 
these cells, since Gαi1 and Go are not expressed 
in macrophages (data not shown).  Inhibition by 
Ptx was similar to that observed for WT cells 
(data not shown). 
UDP binds to purinergic receptors of the 
P2Y family, which usually signal through 
members of the Gαq family (12,28,29). In 
accord with this, we found, that the Ca2+ 
response was completely lost in BMDM from 
Gαq-deficient mice (Fig. 2B).  Surprisingly, 
although BMDM express other members of the 
Gαq family, including Gα11 and Gα15 (Fig. 
2C), these are evidently unable to substitute for 
Gαq in the response to UDP.  Further, the 
BMDM from Gα11-deficient mice had no 
reduction in Ca2+ responses for UDP (or for C5a, 
data not shown) compared with wildtype. 
UDP only binds with high affinity to the 
P2Y6 receptor on macrophages.  UTP, which 
has much lower affinity for P2Y6, binds also to 
P2Y2 and P2Y4 receptors (12,28).  To 
demonstrate that the responses to UDP did not 
involve contaminating UTP, we separately 
tested UTP and UDP before and after treatment 
with hexokinase (12), which catalyzes 
conversion of UTP to UDP. Hexokinase 
treatment of UDP had no effect on its capacity to 
increase [Ca2+]i in BMDM (not shown), 
indicating that contaminating UTP was not 
responsible for the observed responses in 
BMDM.  The efficacy of hexokinase treatment 
was confirmed by showing that hexokinase 
treatment of UTP ablated its capacity to increase 
[Ca2+]i in NIH 3T3 cells, which respond to UTP 
but not UDP 
The removal of either Gαq or Gαi, via 
genetic deletion or Ptx intoxication, respectively, 
also eliminated any synergistic Ca2+ response to 
dual ligand stimulation (Fig. 2D).  Thus, synergy 
between C5a and UDP is dependent on the Gi 
and Gq-linked subunit effectors that are 
activated by C5a and P2Y6 receptors, 
respectively. 
Lysophosphatidic Acid (LPA) and platelet 
activating factor (PAF) also synergize with C5a 
for Ca2+ responses.  To determine whether 
synergy for Ca2+ signaling occurred with other 
ligand pairs, we also examined responses to C5a 
or UDP in combination with PAF or LPA, both 
of which induce a Ca2+ response in macrophages 
through GPCRs.  Pairing of C5a with either PAF 
or LPA demonstrated a robust synergy in Ca2+ 
signaling.  Little or no synergy was seen with 
UDP/PAF, UDP/LPA or PAF/LPA (data not 
shown).  The levels of synergy observed for C5a 
paired with LPA or PAF (Fig. 3A and B) were 
comparable to those for C5a paired with UDP. 
PAF and LPA, like UDP, signaled Ca2+ 
primarily through Gαq in BMDM (Fig. 3C), but 
unlike UDP this was not exclusive; in the Gαq-
deficient cells residual Ca2+ responses for PAF 
were abrogated by Ptx, indicating a minor 
contribution from Gαi-coupled pathways. Ptx 
did not reduce the Ca2+ response to LPA, but 
instead surprisingly enhanced it in both Gαq-
deficient and wt BMDM (Fig. 3D).  These data 
suggest for the first time that Gαi-coupled 
receptors basally inhibit LPA Ca2+ signaling.  As 
with UDP, synergy by either LPA or PAF with 
C5a was lost in Gαq-deficient BMDM (data not 
shown).  Thus, although these receptors can 
activate some Ca2+ signaling independently of 
Gαq, synergy with C5a nonetheless requires 
Gαq activation. 
Overall, these results indicate that the 
simultaneous activation of Gαq and Gαi 
heterotrimers results in a synergistic Ca2+ 
response in macrophages.  C5aR was the only 
endogenous Gαi-coupled GPCR on BMDM that 
we found to be capable of generating a robust 
Ca2+ response independently, and it was also the 
only receptor that synergized with ligands for 
Gαq-coupled receptors.  
Synergy requires dual receptor occupancy.  
We next examined the possibility that one ligand 
might prime cells for subsequent responses, for 
example by increasing the supply of PIP2 to 
provide a heightened state of responsiveness to 
the second stimulus (30). Although synergy was 
greatest when C5a and UDP were added 
simultaneously, it was also evident when ligands 
were added as much as 10 min apart.  The 
sequence of addition was irrelevant.  Fig. 4A 
shows the results for ligands separated by 100 
sec.  However, removal of the first ligand during 
the interim eliminated synergy (Fig. 4B).  Thus, 
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if either ligand primes the synergistic response, 
this effect is rapidly lost.  Functionally, synergy 
requires simultaneous receptor occupancy by 
both ligands. 
Synergy affects the initial release of Ca2+ 
from intracellular stores and IP3 production.  
Synergy between C5a and UDP affected the 
early rise in [Ca2+]i, suggesting an effect on the 
release of intracellular calcium stores.  To test 
this, the Ca2+ responses to C5a and UDP, either 
alone or in combination, were measured after 
acute addition of EGTA to deplete extracellular 
Ca2+.  Synergy occurred in the presence of 
EGTA, confirming an effect on the release of 
intracellular Ca2+ (Fig. 4C). Without EGTA, 
however, synergy also extended to the sustained 
phase response, which is dependent on the influx 
of extracellular Ca2+.  Thus, synergy between 
C5a and UDP begins with the release of 
intracellular Ca2+ stores but extends to the influx 
of extracellular Ca2+. 
The release of Ca2+ from intracellular stores 
is activated by IP3 binding to IP3 receptors on 
the endoplasmic reticulum to open ER calcium 
channels (1). Simultaneous stimulation of 
BMDM with C5a and UDP in amounts that 
produced a synergistic Ca2+ response also 
resulted in synergy in the production of IP3 (Fig. 
4D), suggesting synergistic mechanisms are 
manifest at the level of PLCβ activation.  Levels 
of IP3 measured at 30 sec and 1 min after ligand 
additions were increased.  Ca2+ levels began to 
decline while IP3 was still rising, indicating that 
levels of [Ca2+]i are not solely regulated by 
levels of IP3. 
The synergistic Ca2+ response is 
independent of feedback pathways involving 
PI3-kinase (PI3K) or PKC.  Downstream of 
GPCR activation, PLCβ may be regulated by 
other signaling components, including those 
generated following the activation of PI3K (by 
Gβγ subunits) or of PKC (by DAG) (5).  In our 
studies, however, inhibition of PI3K by 
LY294002 or of PKC by Calphostin C or 
staurosporine did not significantly affect synergy 
(supplemental Fig. S2.).  The activity of the 
inhibitors was confirmed by inhibition of Akt or 
MARCKS phosphorylation (supplemental Fig. 
S3)  These data are further evidence that an early 
signaling event is involved in the mechanism of 
synergy.  
C5a and UDP make selective use of PLCβ 
isoforms.  To examine the role of PLCβ in the 
signaling response to C5a and UDP, we first 
determined levels of transcripts for PLCβ 
isoforms in RAW264.7 cells and in BMDMs.  
By both microarray analysis (data not shown) 
and by RT-PCR (Fig. 5), we found that both cell 
types express PLCβ2, PLCβ3, and PLCβ4, with 
little or no PLCβ1.  At the transcript level, the 
proportions of these PLCβ isoforms, however, 
differ between RAW264.7 cells and BMDM; 
normalized to PLCβ3, RAW264.7 cells express 
similar levels of transcripts for PLCβ2, PLCβ3 
and PLCβ4, while BMDM express PLCβ2 
>PLCβ3 >PLCβ4. 
To determine if C5a and/or UDP made 
selective use of these PLCβ isoforms, we 
examined the Ca2+ response in BMDM from 
mice genetically deficient in PLCβ2, PLCβ3, or 
PLCβ4.  BMDM from mice deficient in PLCβ3 
demonstrated a marked loss of signaling in 
response to all GPCR ligands, including, C5a, 
UDP, PAF and LPA (Fig. 6 and Table1).  
Activation of Ca2+ responses, however, was 
intact in response to ligation of FcγRI by 
crosslinked IgG2a (Fig. 6), demonstrating that 
macrophages from PLCβ3-deficient mice are not 
deficient in the generation of [Ca2+]i to a non-
GPCR ligand.  In BMDM from mice deficient in 
PLCβ4, the Ca2+ response to UDP was also 
consistently reduced, while the response to C5a 
was slightly elevated (Table 1, Fig. 6) and FcγRI 
signaling was normal.  No loss of signaling to 
either UDP or C5a was seen in BMDM from 
mice deficient in PLCβ2.  Thus, in BMDM, 
signaling by both C5a and UDP is selectively 
dependent on PLCβ3, but signaling by UDP is 
also partly dependent on PLCβ4. 
To examine the role of PLCβ in RAW264.7 
cells, we used RNAi against the different PLCβ 
isoforms.  The loss of PLCβ isoforms in 
response to RNAi was incomplete (supplemental 
Fig. S4), but this approach allowed the testing of 
a uniform cell line, and it avoided possible 
developmental effects on macrophages due to 
PLCβ isoform loss.  The depletion of PLCβ3 
from RAW264.7 cells by RNAi reduced 
signaling by C5a, though not to the same extent 
as in BMDM genetically deficient in PLCβ3 
(Table 2).  Cells depleted of PLCβ3 by RNAi 
were not deficient in their response to UDP, but 
RNAi against PLCβ4, caused a loss of signaling 
in response to UDP, with a slight elevation in 
C5a signaling (Table 2).  Thus, signaling by C5a 
depends mostly on PLCβ3 in both BMDM and 
RAW264.7 cells.  Signaling by UDP is partially 
dependent on PLCβ3 in BMDM, but we could 
not detect this dependency in RAW264.7 cells 
by RNAi of PLCβ3.  Signaling by UDP is also 
dependent on PLCβ4 in both BMDM and 
RAW264.7 cells, while deficiency of PLCβ4 
augments C5a signaling in both cells. 
Ca2+ responses are restored in PLCβ3-
deficient BMDM reconstituted with PLCβ3. 
Retroviruses were used to transduce wildtype 
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and PLCβ3-deficient BMDM with either YFP-
tagged murine PLCβ3 or control YFP-tagged 
FLAG cDNAs.  Single-cell calcium assays were 
performed, which allowed identification of 
transduced cells by YFP fluorescence and 
comparison of responses by transduced and non-
transduced cells (Fig. 6 B, C). Reconstitution of 
PLCβ3-deficient BMDM with PLCβ3 
reconstituted the Ca2+response to both C5a and 
UDP, alone and in combination, indicating that 
the loss of Ca2+ response in the PLCβ3-deficient 
cells is not due to an associated developmental 
defect.  
Synergistic Ca2+ responses also show 
isoform dependence.  We next tested the role of 
the PLCβ isoforms in synergy between C5a and 
UDP.  In BMDM lacking PLCβ3 or PLCβ4, 
only those deficient in PLCβ3 were deficient in 
synergy (Fig. 7A and Table 3), as reflected by a 
reduced synergy ratio.  Because signaling by 
individual ligands was lower than wildtype in 
these cells, the predicted additive responses were 
also lower, but a residual synergistic response 
was still detected in PLCβ3 deficient cells 
(Table 3).  Thus synergy in Ca2+ signaling, like 
signaling by individual ligands, is primarily 
dependent on PLCβ3, but some synergy can be 
seen without it, Notably, lack of PLCβ4 did not 
reduce synergy in BMDM but instead enhanced 
it.  We conclude that PLCβ3, but not PLCβ4, 
plays an important role in synergy between these 
ligands as well as in their individual responses.  
As with Ca2+ signaling, BMDM lacking 
PLCβ3, but not PLCβ4, failed to demonstrate 
synergy in the production of IP3 (Fig. 7B).  
Thus, studies of both Ca2+ and IP3 indicate that 
synergy in signaling by C5a and UDP is the 
result of enhanced activity of PLCβ3. 
Dual-ligand effects on PI3-kinase contrast 
to those on PLC.  In order to determine if the 
synergistic effects of C5a plus UDP dual ligand 
stimulation were reflected in signaling events 
other than PLC activation, we examined 
activation of PI3K. Gβγ subunits directly 
activate PI3K-p110γ (31) and GPCRs can also 
activate PI3K-p110α and PI3K-p110β (32).  The 
Gαq subunit does not activate PI3K, but instead 
can interact with and inhibit PI3K-p110α 
(33,34).  Thus, PI3K activity reflects important 
proximal GPCR signals.  To assess activation of 
PI3K, we measured the phosphorylation of Akt, 
which requires anchoring of its PH domain to 
PIP3 produced by PI3K at the cell membrane.  In 
BMDM, C5a rapidly activated PI3K, with peak 
phosphorylation of Akt at ~3 min (data not 
shown).  In contrast, UDP did not activate PI3K, 
and it inhibited the phospho-Akt response to C5a 
(Fig. 8).  This inhibition of Akt phosphorylation 
by UDP was at least partially selective, as ERK 
phosphorylation showed additivity.  UDP did 
not inhibit PI3K activation in response to the 
crosslinking of FcγRI (data not shown), 
demonstrating that signaling by UDP did not 
globally interfere with all forms of PI3K 
activation.  The observation that UDP inhibits 
PI3K activation by C5a while promoting Ca2+ 
signaling suggests that these pathways are 
differentially regulated.  
The opposing effects of C5a/UDP signal-
interactions on PLC and PI3K are reflected in 
macropinocytosis.  Macropinocytosis, the 
endocytic process whereby cells internalize 
substantial volumes of extracellular fluid and 
solutes, is dependent on both PLC and PI3K 
(35,36), and this ‘sampling’ of the environment 
contributes to macrophage antigen presentation 
(37,38).  We found that C5a activates 
macropinocytosis by BMDM, while UDP does 
not.  Macropinocytosis was inhibited by dual-
ligand stimulation (Fig. 9), in contrast to 
synergy for PLC and Ca2+ but in parallel with 
the inhibition of PI3K.   
 
DISCUSSION 
 
Our studies demonstrate the preferential use 
of PLCβ isoforms by GPCRs in eliciting a Ca2+ 
response in macrophages.  Further, they indicate 
that synergy in signaling by the Gαi-coupled 
C5aR, together with the Gαq-coupled P2Y6 
receptor for UDP, depends on a selective use of 
PLCβ3.  Synergy in the Ca2+ response to C5a 
and UDP correlated with synergy in IP3 
production, suggesting signal convergence at the 
level of PLCβ activation.  In contrast to Ca2+ 
activation, synergy between C5a and UDP was 
not observed in PI3K activation.  Instead, the 
activation of PI3K by C5a was opposed by 
UDP.  A similar effect was seen in the activation 
of macropinocytosis, which is dependent on both 
PLC and PI3K.  Thus, synergy was selective for 
IP3 production and the Ca2+ response, consistent 
with a selective effect on PLCβ. 
The preferential use of PLC isoforms by 
GPCRs in macrophages did not simply reflect 
differential levels of expression of transcripts for 
the PLCβ isoforms.  Four isoforms of PLCβ 
have been identified (4). We found that both 
BMDM and RAW264.7 cells expressed 
transcripts for PLCβ2, β3 and β4 but not 
PLCβ1, as determined by gene array analyses on 
Affymetrix chips and by RT-PCR.  We have not 
been able to develop assays that adequately 
quantify differences in protein expression of 
these PLCβ isoforms, but our results nonetheless 
suggest that the selective use of PLCβ3 in 
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macrophages for Ca2+ signaling and synergy is 
despite the expression of PLCβ2 and PLCβ4.  
Thus, in contrast to platelets and neutrophils, 
PLCβ3 appears to be the major functional 
isoform in macrophages.  While this paper was 
in preparation, Wang et al, also reported reduced 
Ca2+ responsiveness to C5a by macrophages 
from PLCβ3-deficient mice, and they linked this 
to increased apoptosis, and diminished 
atherosclerosis (39).  Our studies demonstrate 
that in macrophages UDP can use PLCβ4 as 
well as PLCβ3, but C5a synergizes with UDP 
and other activators of Gαq through signals that 
converge at the level of PLCβ3, and 
responsiveness can be restored by transduction 
of cells with PLCβ3, showing that the defect in 
signaling does not reflect developmental 
changes in other pathways. 
Synergy in the macrophage Ca2+ response 
was observed both in the initial, rapid release of  
Ca2+ from intracellular stores and in the 
sustained elevation of cytoplasmic Ca2+ levels. 
This observation is important, as there are 
examples of ligand interactions that increase 
[Ca2+]i only via the influx of Ca2+ through 
plasma membrane Ca2+ channels (40). 
Synergy between Gαi- and Gαq-coupled 
receptors has previously been observed in other 
cell types.  In several systems, including smooth 
muscles, astrocytes, and kidney epithelial cells, 
Gαi-coupled GPCRs may alone not trigger a 
Ca2+ response, but responses may be facilitated 
in combination with, or after priming by, Gαq-
coupled receptors (41-43).  This synergy is 
reflected in the generation of IP3, as in our 
current studies of macrophages, implicating PLC 
in the pathway of synergy. 
Our findings narrow the possible 
mechanisms by which synergy in Ca2+ signaling 
by macrophages may occur.  All PLCβ isoforms 
can bind Gαq subunits, albeit with differing 
affinities (44-48), and under certain conditions 
PLCβ4 demonstrates the highest specific activity 
for hydrolyzing PIP2 (49).  Consistent with this, 
the absence of PLCβ4 reduced mobilization of 
[Ca2+]i by all ligands that activate Gαq, 
including UDP, LPA, and PAF.  The loss of 
PLCβ4, however, did not impair synergy but 
instead increased it.  Thus, PLCβ4 appears to 
inhibit rather than promote synergy in 
macrophages.  PLCβ2 and β3 are both potently 
activated by Gβγ (25,47,50,51), while PLCβ4 is 
not (49).  Although most Ca2+ synergy was lost 
in mice lacking PLCβ3, we could still detect low 
levels of synergy.  We hypothesize that PLCβ2 
may be capable of mediating synergy, but in 
macrophages the contribution of PLCβ2 is small 
in relation to that of PLCβ3. 
In all, these results suggest that synergy 
between C5a and UDP in Ca2+ signaling in 
macrophages does not require multiple isoforms 
of PLCβ but instead involves the convergence of 
molecular mechanisms that primarily activate 
PLCβ3, but which may to a lesser extent activate 
PLCβ2.  
Synergy between the Gαi receptor C5aR 
and Gαq receptors, does not establish that Gαq 
itself participates in the synergy.  Gβγ signaling 
may differ between C5a and UDP, and synergy 
could reflect interactions between their unique 
Gβγ pathways.  Indeed, loss of Gβ2 subunits via 
RNAi disrupts C5a but not UDP Ca2+ responses 
in RAW264.7 cells ((52), and data not shown). .  
In our studies, C5a synergized not only with 
UDP, but also with PAF and LPA in stimulating 
a rise in [Ca2+]i.  Studies of Gαq-deficient 
BMDM confirmed that both PAF and LPA 
utilize Gαq, but they also revealed important 
and interesting differences between these ligands 
and UDP.  Unlike UDP, neither PAF nor LPA 
was fully dependent on Gαq.  The remaining 
Ca2+ signaling with PAF utilized Gαi, as 
interruption of this pathway with Ptx in the 
absence of Gαq removed all Ca2+ signaling in 
response to PAF.  In contrast, LPA Ca2+ 
signaling was not reduced by Ptx.  Instead it was 
markedly increased.  The G proteins used by 
LPA to elevate [Ca2+]i in Gαq-deficient BMDM 
are unknown, but it appears that they are 
normally inhibited by Gαi. 
At high ligand concentrations, C5a also 
demonstrated some Ptx-insensitive activation of 
Ca2+ signaling.  We found that this response was 
still present in Gαq- or Gα11-deficient mice, 
suggesting coupling of C5aR to the more 
promiscuous Gα15, as has been observed by 
others (27).  However, no Ca2+ synergy was 
observed with the combination of two Gαq-
family linked ligands.  Optimal synergy was 
observed at low concentrations of C5a, where 
the C5a-stimulated Ca2+ response was entirely 
Ptx sensitive, so we infer that the synergy is 
attributable to the Gαi activation by C5aR.  In 
BMDM, the C5a receptor was the only Ca2+ 
signaling receptor identified that was primarily 
dependent on Gαi. 
GPCR-mediated PLCβ activation can be 
regulated by positive or negative feedback loops.  
The PH-domain of PLCβ preferentially binds to 
the phosphatidylinositiol-3-phosphate (PI3P) 
product of PI-3K (4) and thus PI3K has the 
potential to modulate PLCβ activity.  In our 
studies, however, inhibition of PI3K by 
LY294002 did not alter the Ca2+ synergy, 
indicating that PI3K does not measurably 
contribute to synergy.  PKC may interact with 
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PLC at several levels.  It can directly 
phosphorylate PLCβ, inactivating it (53).  It can 
also phosphorylate and regulate signaling via 
GPCRs, and can phosphorylate some G protein-
coupled receptor kinases (GRKs) (54).  In our 
studies, however, inhibition of PKC with either 
Calphostin C or staurosporine did not alter Ca2+ 
synergy. 
The acute nature of the synergy observed 
(occurring within seconds of dual ligand 
addition) and the demonstrated requirement for 
simultaneous dual receptor occupancy argue 
against the possibility that one receptor might 
drive ‘priming’ events affecting responses to the 
second receptor.  Mechanisms for synergy 
reflecting priming effects have been proposed in 
a number of other systems (55).  The immediate 
synergy in macrophages precludes changes in 
receptor or other protein expression levels.  
Alternatively, a priming event could increase the 
supply of the PLC substrate PIP2 to enhance 
production of IP3 (56-58), and in some cases this 
has been shown to persist for hours after first 
ligand stimulation.  This synergy mechanism 
would not require dual receptor occupation 
during heterologous ligand stimulations of Ca2+ 
unless increases in the supply of PIP2 were lost 
rapidly (we tested 3 minutes after 1st ligand 
removal by which time synergy was lost). 
The consequences of combined signaling by 
C5a and UDP in macrophages may be 
particularly important in areas of inflammation, 
where C5a is produced, and where UDP may be 
released from dying cells (59).  C5a in particular 
plays a central role in inflammation, and 
consequences of Ca2+ signaling would be 
augmented by UDP, while consequences of 
PI3K activation would be inhibited.  The recent 
report describing a reduction of atherosclerosis 
in PLCβ3-deficient mice, due to macrophage 
hypersensitivity to apoptotic induction, links 
inflammatory outcome to Ca2+ signaling and 
survival in macrophages (39). 
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FIGURE LEGENDS 
 
Table 1. Single-ligand Ca2+ responses in PLCβ isotype-deficient BMDM.  BMDMs derived from 4-7 
individual PLCβ-deficient (-/-) mice per isoform were subjected to Ca2+ assays for near maximal 
concentrations of several GPCR ligands: C5a (10 nM), UDP (2.5 µM), LPA (2.5 µM), and PAF (12.5 
nM).   Three to four assays per cell population & ligand were performed, with 3-4 replicate samples per 
assay.  Responses were normalized to the matched WT BMDMs in each assay and the table reports the 
average response of each isotype -/- as a % of WT response.  Values are shown for peak-offset and 
integration to 60 sec measurements of the Ca2+ responses.  PLCβ3-deficient BMDM showed reduced 
responsiveness to four GPCR ligands but not following ligation of FcγRI (FCG).  PLCβ4-deficient 
BMDM showed a reduced Ca2+ response phenotype for UDP only. * p<0.05, ** p<0.005. 
 
Table 2. RNAi against PLCβ3 and PLCβ4 in RAW264.7 reduces Ca2+ responses to C5a and UDP 
respectively.  RNAi against PLCβ isoforms in RAW264.7 cells was performed by lentiviral-mediated 
RNAi using shRNA encoding constructs.  Control lines lacking only shRNA were prepared and analyzed 
in parallel with each RNAi line.  Ca2+ assays were performed with C5a (30nM) and UDP (25 µM) and 
responses were quantified by peak offset and integration to 1 or 2.5 min after ligand addition.  Values 
were normalized to responses of control lines in each assay, and results of replicate lines were pooled to 
present the average response as a percent of control.  Results represent 2-5 lines per target with 3-4 assays 
per line and 3-4 samples per ligand per assay. * p<0.05, ** p<0.01. 
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Table 3. Ca2+ response synergy in PLCβ isotype-deficient BMDMs. BMDMs derived from individual 
PLCβ isotype-deficient mice were subjected to Ca2+ assays for synergy between C5a and UDP (0.75 nM 
+ 500 nM).  Peak-offset values from Ca2+ responses by Fura-2 loaded cells were normalized to 
corresponding controls in each assay.  Data were pooled to report average values as a percent of control 
(%WT) for the individual ligands and corresponding predicted additive responses.  Synergy observed was 
reported as a percent of the calculated additive Ca2+ response for each cell type.  Data were from 6 or 4 
independent lines for PLCβ3 or PLCβ4-deficient cells respectively, with 2-4 replicate assays per 
population and 3-4 samples per condition per assay. * p<0.05, ** p<0.005.  
 
Fig 1. UDP and C5a produce a synergistic Ca2+ response in macrophages. Intracellular Ca2+ levels were 
calculated for Fura-2-loaded adherent macrophage populations from kinetic assays in 96-well plates.  
After 40 sec baseline readings, ligands were added and responses were monitored for 2.5 min.  Each line 
in the graphs represents the average of 3-4 individual wells per assay and the error bars (SEM) are shown 
for the dual-ligand line in each graph.  Synergy was evaluated by comparing the experimentally observed 
dual ligand responses to the predicted additive responses of the individual ligands.  The dual-ligand 
response was quantified as the ratio of the observed/predicted additive responses and the term ‘synergy 
ratio’ was applied to the ratio of the peak offsets (PO = peak height – baseline).   
A. RAW264.7 cells were stimulated with UDP (2.5 µM), C5a (10 nM) or simultaneous UDP and C5a .  
Synergy ratio = 1.38.  This is a representative experiment of n=12 with similar results.   
B. BMDM were stimulated with UDP (500 nM), C5a (0.37 nM) or simultaneous UDP and C5a.  Synergy 
ratio = 2.62.  This is a representative experiment of >25 with similar results. 
C. Dose-response pattern for simultaneous UDP and C5a-stimulated Ca2+ responses quantified by synergy 
ratio.  Ligand concentrations are expressed as log(nM).  The optimal synergy ratio was at  ~ 300 nM UDP 
+ 0.3 nM C5a.  The surface was interpolated from 84 individual experiments composed of 15 samples 
each. 
  
Fig 2. Synergy Requires Gαq- and Gαi-heterotrimer subunit effectors.  Intracellular Ca2+ responses were 
measured in Fura-2-loaded BMDMs. 
A. C5a Ca2+ responses are mostly Ptx sensitive.  BMDM cultured overnight with or without Ptx (100 
ng/ml) were stimulated with different concentrations of C5a (0.33 to 10 nM), or a single concentration of 
UDP (2.5 µM), and the peak offset of the Ca2+ responses was determined.  Shown is a representative 
experiment of 7 with similar results.  Values are mean+/-SEM of 3-4 replicate samples per condition.  * 
p<0.01. 
B. UDP responses are Gαq-dependent.  Wildtype (WT), Gαq heterozygote (+/-) and Gαq-deficient (-/-) 
BMDM  were stimulated with either UDP (2.5 µM) or C5a (10 nM).  Peak-offsets of responses are shown 
normalized to those of the wildtype cells from each experiment.  Values are mean+/-SEM from 3 
experiments. * p<0.001. 
C. Quantitative RT-PCR for Gαq family isoforms q, 11, and 15 was performed on RAW264.7 cell and 
BMDM samples to determine relative prevalence. Transcript levels were normalized to those for Gαq for 
the same cell type.  Data shown are mean +/- SEM from n=3 samples per cell. 
D. Synergy following dual ligand stimulation requires both Gαq and Gαi subunits.  Wildtype (WT) or 
Gαq-deficient (-/-) BMDM were stimulated with UDP (500nM), C5a (0.75 nM), or simultaneous UDP 
and C5a.  WT cells were cultured overnight with or without Ptx (100 ng/ml).  Data shown are from a 
representative experiment of 3-4 with similar results.  Each line in the graphs represents the average of 3-
4 individual wells in the assay.   
 
Fig 3. LPA and PAF also show synergy with C5a in Ca2+ responses, and they couple mainly with Gαq.  
Intracellular Ca2+ responses were measured in Fura-2 loaded BMDMs.  Each line in the graphs represents 
the average of 3-4 individual wells per assay. 
A. BMDM were stimulated with C5a (0.25 nM), LPA (0.25 nM) or simultaneous C5a and LPA.  Data 
shown are from a representative experiment of n=18 with similar results. 
B. BMDM were stimulated with C5a (0.25 nM), PAF (0.3 nM) or simultaneous C5a and PAF.  Data 
shown are from a representative experiment of n=17 with similar results. 
C. WT or Gαq-/- BMDM were stimulated with UDP (10 µM), PAF (12.5 nM) or LPA (2.5 µM). Data 
shown are from a representative experiment of n=8-14 with similar results. 
D. WT or Gαq-/- BMDM  were cultured overnight with or without Ptx and then stimulated with PAF 
(12.5 nM) or LPA (2.5 µM).  Data shown are from a representative experiment of 4-5 with similar results. 
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Fig 4. C5a and UDP produce synergistic Ca2+ responses when added serially, but synergy requires dual 
ligand receptor occupancy.  Intracellular Ca2+ responses were measured in Fura-2-loaded BMDM.  Each 
line in the graphs represents the average of 3-4 individual wells per assay. 
A. Serial addition of stimuli to BMDM provides synergy.  C5a (0.75 nM), UDP (500 nM) or HBSS were 
added at the first time point (arrow 1), and after a 100 sec delay UDP or C5a was added at the second 
time point (arrow 2).  The first stimulus was not removed prior to addition of the second. 
B. Serial stimulation of BMDM does not provide synergy if the first ligand is removed prior to addition of 
the second.  Either UDP (500 nM) or HBSS was added to the cells and incubated for 2 min.  The buffer 
was then left in the wells another 3 min or the buffer was removed, the cells washed, and fresh buffer 
replaced in the wells.  Either C5a (0.75 nM), C5a + UDP (0.75 nM + 500 nM), or HBSS was then added 
to the wells (2nd addition, arrow labeled “2”, 5 min delay from 1st addition, thus 3 minute delay after 1st 
ligand removal for washed samples), and the results of the second response period are shown.  The left 
panel depicts responses to the 2nd stimulus when the first ligand remains.  The right panel depicts 
responses to the 2nd ligand in the absence of the 1st ligand. 
C. Synergy was observed in the release of Ca2+ from intracellular stores.  Each line in the graphs 
represents the average of 3-4 individual wells per assay.  HBSS or EGTA (2 mM) was added to assay 
wells 30 sec prior to C5a (0.75 nM), UDP (500 nM) or simultaneous C5a and UDP. 
D. IP3 responses of BMDMs.  Cells were stimulated with C5a (10 nM), UDP (2.5 µM), or simultaneous 
C5a and UDP for 0, 30 sec, or 1 min and signaling was stopped by cell lysis in perchloric acid as 
described for IP3 measurements.  IP3 was measured using a competitive binding assay for the IP3 receptor 
and results are reported as pmol / 106 cells.  Values shown are mean +/- SEM from n=5-10 samples per 
condition.    
 
Fig 5.  Selective use of the PLCβ3 and β4 isoforms in GPCR signaling in BMDM did not correlate with 
higher levels of expression. Quantitative RT-PCR for PLCβ isoforms 1, 2, 3, and 4 was performed on 
RAW264.7 cell and BMDM samples to determine relative prevalence. Transcript levels were normalized 
to those for PLCβ3 for the same cell type.  Data shown are mean +/- SEM from n=3-4 samples per cell.  
Little to no expression of PLCβ1 mRNA was observed, as shown. 
 
Fig 6. PLCβ isoform-dependence of Ca2+ responses.  
A. Ca2+ responses for C5a, UDP, LPA and PAF are reduced in PLCβ3-deficient BMDM compared to 
wildtype, but only the UDP response is reduced in PLCβ4-deficient BMDM. Intracellular Ca2+ responses 
were measured in Fura-2-loaded BMDM.  Cells were stimulated with near-maximal doses of the 4 ligands 
tested: C5a (10 nM), UDP (10 µM), LPA (2.5 µM) or PAF (12.5 nM), or by FcγR cross-linking (cells 
preloaded with 5 µg/ml IgG2a, then treated with 44 µg/ml F(ab’)2 antibody fragments of rabbit anti-
mIgG).  Each line in the graphs represents the average of 3-4 individual wells per assay.  Representative 
experiments are shown for matched wildtype versus PLCβ3- or PLCβ4-deficient (-/-) cells from n=8-33 
assays with similar results.  Assays were performed on 12 PLCβ3-deficient and 4 PLCβ4-deficient 
BMDM cultures which were independently derived. 
B. Expression of PLCβ3 in PLCβ3-deficient BMDM restores single-ligand Ca2+ responses. Single cell 
Ca2+ assays were performed on wildtype (WT) or PLCβ3-deficient BMDM transduced with retrovirus 
encoding YFP-FLAG or YFP-PLCβ3.  Cells were stimulated with C5a (10 nM) and peak-offset features 
of the Ca2+ traces calculated.  Responses by transduced cells were measured in multiple assays of each of 
2 independent batches of infected BMDM.  Values shown are mean +/- SEM from n=3-9 samples per 
condition. *p<0.05. 
C. Expression of PLCβ3 in PLCβ3-deficient BMDM restores dual-ligand Ca2+ responses to levels 
observed in WT BMDM.  Single cell Ca2+ assays were performed on wildtype (WT) or PLCβ3-deficient 
BMDM transduced with retrovirus encoding YFP-FLAG or YFP-PLCβ3.  Cells were stimulated with C5a 
(0.75 nM), UDP (500 nM), or C5a+UDP, and the Ca2+ responses were measured by integration over 2.5 
min.  Responses by transduced cells were measured in multiple assays of each of 3 independent batches 
of infected BMDM.  Values shown are mean +/- SEM from n=11-17 samples per condition.  *p<0.05. 
 
Fig 7. The synergistic Ca2+ response shows selective use of the PLCβ3 isoform.  Matched wildtype (+/+) 
versus PLCβ3- or PLCβ4-deficient (-/-) BMDMs were assayed for their ability to reflect synergistic 
responses to C5a plus UDP.   
A.Intracellular Ca2+ responses were measured in Fura-2-loaded BMDM.  Each line in the graphs 
represents the average of 3-4 individual wells per assay.  Cells were stimulated with C5a (0.75 nM), UDP 
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(500 nM) or both ligands.  Data shown are from representative experiments of n=9-19 with similar 
results.  
B. IP3 production in PLCβ isoform-deficient BMDM.  Cells were stimulated with C5a (10 nM), UDP (2.5 µM), or simultaneous C5a and UDP as indicated, and signaling was stopped by cell lysis at 1 min after 
stimulation.  IP3 was measured using a competitive binding assay for the IP3 receptor, and results are 
reported as pmol / 106 cells.  Data represent pooled results from 2-4 assays with 2 replicate samples per 
condition per assay. * p<0.005. 
 
Fig 8. UDP and other Gαq-coupled ligands antagonize C5a stimulation of PI3-kinase. 
Adherent BMDM were stimulated with C5a (10 nM), UDP (10 µM), LPA (2.5 µM), PAF (50 nM), C5a 
plus UDP, C5a plus LPA or C5a plus PAF.  After 1 min of stimulation, the assay was stopped by sample 
lysis.  Western blots were probed with specific antibodies and were quantified by using a phosphor-
imager.  Phosphoprotein values were normalized to levels of RhoGDI in the samples and then expressed 
as a fold-increase above the baseline level, represented by the average of control cell samples not 
stimulated with specific ligands.  Data are shown for P-Akt and P-ERK from nine replicate experiments 
as mean+/-SEM. * p<0.05, ** p<0.01. 
 
Fig 9. UDP inhibits C5a-stimulated macropinocytosis.  BMDM were stimulated with or without C5a (0, 
0.3, 0.75, 2.5 nM) in the presence or absence of UDP (0, 0.5, 2.5 µM) in assays of macropinocytosis.  
Uptake of extracellular FITC-dextran was assessed by cytometry and normalized to the positive control 
(C5a 0.75 nM) in each assay (arbitrary units, AU) for summary purposes.  Values show the mean +/- 
SEM from 8 experiments (n=4-8 per condition). 
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Ligand WT PLCβ2-/- PLCβ3-/- PLCβ4-/-
C5a 100 118±19  20±4** 104±6
UDP 100 150±32  44±3**  81±6*
LPA 100 109±13  24±4**  86±13
PAF 100 136±4*  38±4**  94±3
FCG 100 114±12 104±10  87±20
C5a 100 131±28  18±3** 105±5
UDP 100 159±40  44±3**  73±6*
LPA 100  98±10  28±5**  89±13
PAF 100 142±9*  34±3**  94±9
Integrated 
60s
Measure 
of 
Response
Peak 
offset
BMDM
Table 1. 
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Table 2. 
RNAi 
Target # Lines
Peak 
Offset
Intgrated 
1m
Integrated 
2.5m
Peak 
Offset
Intgrated 
1m
Integrated 
2.5m
PLCβ2 2   71     58    82**   104     78    104
PLCβ3 2   61*     46*    62*   107    110    111
PLCβ4 5  125**    115   111    97     95     88*
C5a UDP
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C5a UDP
Calculated   
Additive
Synergy       
Observed
BMDM (%WT) (%WT) (%WT)
% of Calculated 
Additive
WT   100   100   100 264±33 
PLCβ3-/-    25±11**   41±5**    34±5** 158±21*
PLCβ4-/-   103±5    61±5*    78±6* 315±38*
Peak Offset Response 
Table 3. 
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